Testing the Addition of Venetoclax and/or Blinatumomab to Chemotherapy for Infants with Newly Diagnosed Leukemia
Phase 2
153
about 3.6 years
≤0.999336057550805
106 sites in AK, AL, AR +37
About this study
Researchers are testing whether adding venetoclax and/or blinatumomab to usual chemotherapy treatment improves outcomes in infants diagnosed with acute lymphoblastic leukemia (ALL) who have a KMT2A gene rearrangement or not. The trial will evaluate the safety and effectiveness of this combination therapy compared to standard chemotherapy alone.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Blinatumomab
- 2.Take Asparaginase Erwinia chrysanthemi
- 3.Take Calaspargase Pegol
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS, blinatumomab, calaspargase pegol, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), cytarabine, daunorubicin, dexamethasone, doxorubicin (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II)
injection (Injection), injection, intravenous, infusion, ocular, oral (Oral Tablet), oral (Disintegrating Oral Tablet), oral
Secondary: 3-year EFS of infants with KMT2A-G ALL treated on Arm C, 3-year EFS of infants with KMT2A-R ALL, Event free survival (EFS) rates of infants with KMT2A-R ALL, Pharmacokinetics (PK) of venetoclax in infants
diagnostic, biopsy, imaging
Oncology